The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Test Protocol for Testing Anti-Viral Efficacy

26 Feb 2021 07:00

RNS Number : 4122Q
Byotrol PLC
26 February 2021
 

 

 

Byotrol Plc

("Byotrol" or the "Company")

 

Landmark test protocol for testing long-lasting anti-viral efficacy

 

 

Byotrol plc (AIM:BYOT), the specialist infection prevention and control company, is pleased to announce that it has developed and externally validated a new test for determining whether cleaning and sanitising products have long-lasting efficacy against viruses in real-life use.

· This new test determines whether sanitising and cleaning products offer any long-lasting protection against COVID-19

· Byotrol is now standing behind product efficacy claims supporting infection control products that offer 24-hour protection against viruses and bacteria in real-life conditions, where surfaces are frequently touched

· The Company believes that this new test could help minimise the spread of the virus when used in conjunction with the cleaning and sanitising of shops, schools and offices when they reopen

Byotrol has developed the new test in response to an increasing number of products claiming long-lasting efficacy against coronavirus, based on laboratory conditions which ignore the constant abrasion of surfaces in real-life environments (and which would then make many products ineffective).

 

Byotrol developed the industry standard test for long-lasting efficacy in real-life against bacteria and yeast in 2014 with the help of independent industry experts. The test, named PAS 2424:2014, was approved by the British Standards Institute (BSI) and is the only British standard to prove the efficacy of a disinfectant product over 24 hours. The PAS 2424:2014 test is currently being reviewed by the CEN Committee for approval as a new European EN test standard.

 

This new test for viruses simulates 'real-life' conditions by creating frequent abrasions on surfaces after products have been applied, to replicate frequent touching of surfaces throughout the day. The surfaces are then tested to see whether the product is still present and killing viruses. The test is limited to 24 hours, to ensure that the result is attributed to the efficacy of the product, not the length of time the virus has been left to dry out on a surface, which could result in a false positive.

 

This new test was performed internally in Byotrol's virology lab with the results being reviewed and validated externally by Professor James Stewart, Chair of Molecular Virology at the University of Liverpool, who commented: "A validation of the effectiveness of surface disinfectants against viruses using this test is an important step forward for the industry and consumers alike."

 

Byotrol plans to gain approval from the BSI again, to make this new test the British standard for proving the long-lasting efficacy of disinfectants against viruses.

 

The application of this test could help businesses and consumers select products which are proven to be effective in a variety of public spaces where surfaces are frequently touched, genuinely promoting public health.

 

 

 

Trevor Francis, Chief Technology Officer of Byotrol plc commented:

 

"Long-term surface protection against viruses is the holy grail that businesses in the hygiene sector are chasing currently. We have responded to a clear market need for clarity on which surface disinfectants continue to deactivate viruses in real-life environments and which don't. It's a huge win for consumers and the government as we return to normality beyond the pandemic."

 

 

Enquiries:

 

Byotrol plc

Trevor Francis - Chief Technology Officer

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer 01925 742 000

 

finnCap

Geoff Nash/Kate Bannatyne - Corporate Finance   020 7220 0500

Richard Chambers - ECM

 

Flagstaff Strategic and Investor Communications

Tim Thompson/Andrea Seymour/Fergus Mellon +44 (0)207 129 1474

byotrol@flagstaffcomms.com

 

 

 

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABLGDDIXDDGBU
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.